Combining Enzalutamide with Radium-223 Significantly Improves rPFS as First-Line Therapy for Patients with mCRPC By Ogkologos - August 27, 2025 416 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PEACE-3 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma Mortality Trends for Most Cancers Remain Favourable In the EU, Although the Absolute Number of Cancer Deaths Is Not Declining Due To Population Ageing MOST POPULAR EMA Recommends Extension of Indications for Ribociclib to Include Use in... November 5, 2024 Comme louer son affaire en compagnie de tacht mahometane? (2023) August 13, 2023 2022 ASCO Annual Meeting Research Round Up: Advances in Treating Genitourinary... June 30, 2022 EMA Recommends Extending Indications for Durvalumab July 17, 2025 Load more HOT NEWS FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single... Embryos in the Womb Can Get Gene Mutations That Lead to... How to Make the Most of Your Patient Portal During Cancer New on NCI’s Websites for September 2020
